EMA Recommends Gohibic for ARDS Induced by SARS-CoV-2
Following a consultation with its emergency task force, the European Medicines Agency (EMA) has backed a drug for adult patients with acute respiratory distress syndrome (ARDS) induced by the SARS‑CoV-2 virus. As a result, the EMA’s Committee for Medicinal Products for Human Use recommended granting a marketing authorization “under exceptional circumstances” for Gohibic (vilobelimab…
Read More
0
